While further investigation into the function of SMYD3 in prostate cancer is necessary, SMYD3 overexpression was associated with worse disease-specific survival in a cohort of 189 prostate cancer patients independently of other known prognostic factors [34]. Here, SMYD3 is linked to prostate cancer.